- Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
-
Kobayashi T, Ito H, Ashida T, Yokoyama T, Nagahori M, Inaba T, Shikamura M, Yamaguchi T, Hori T, Pinton P, Watanabe M, Hibi T
- KMID: 2521608
- Intest Res.
- 2021 Oct;19(4):448-460.
- doi: 10.5217/ir.2020.00026
Background/Aims: A subgroup analysis was conducted in Japanese patients with moderate to severe ulcerative colitis (UC) enrolled in the phase 3 VISIBLE 1 study, which evaluated the safety and efficacy... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study
-
Hibi T, Motoya S, Ashida T, Sai S, Sameshima , Nakamura S, Maemoto A, Nii M, Sullivan B, Gasser Jr , Suzuki Y
- KMID: 2454746
- Intest Res.
- 2019 Jul;17(3):375-386.
- doi: 10.5217/ir.2018.00141
BACKGROUND/AIMS: Inhibition of α4β7 integrin has been shown to be effective for induction and maintenance therapy in patients with ulcerative colitis (UC). We investigated the effects of varying doses of... -
- CITED
-
- Close
- SHARE
-
- Close
